Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on Afabicin PK in Healthy Subjects
NCT03209648Phase 1Completed
- Sponsor
- Debiopharm
- Start
- Jun 2017
- Primary completion
- Aug 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of afabicin in Staphylococcus aureus infection, sponsored by Debiopharm. Primary endpoints: Maximum Observed Plasma Concentration of Debio 1452, Area Under the Plasma Concentration-time Curve from Time Zero to Infinity of Debio 1452 and 1 more. Started Jun 2017; status: completed.
02
Drugs
afabicin
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT03209648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03209648.